{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T16:51:43Z","timestamp":1790095903154,"version":"4.0.1"},"reference-count":11,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2019,9,30]],"date-time":"2019-09-30T00:00:00Z","timestamp":1569801600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006484","name":"Vifor Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006484","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,8,1]]},"DOI":"10.1093\/ckj\/sfz129","type":"journal-article","created":{"date-parts":[[2019,8,30]],"date-time":"2019-08-30T11:48:51Z","timestamp":1567165731000},"page":"714-719","source":"Crossref","is-referenced-by-count":20,"title":["Recurrent hyperkalaemia management and use of renin\u2013angiotensin\u2013aldosterone system inhibitors: a European multi-national targeted chart review"],"prefix":"10.1093","volume":"13","author":[{"given":"Patrick","family":"Rossignol","sequence":"first","affiliation":[{"name":"Universit\u00e9 de Lorraine, Inserm, Centre d\u2019Investigations Cliniques-Plurith\u00e9matique 14-33, Inserm U116, CHRU Nancy, F-CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists), Nancy, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis M","family":"Ruilope","sequence":"additional","affiliation":[{"name":"Hypertension Unit, Instituto de Investigaci\u00f3n imas12, Hospital Universitario, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adamasco","family":"Cupisti","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Ketteler","sequence":"additional","affiliation":[{"name":"Department of General Internal Medicine and Nephrology, Robert-Bosch-Krankenhaus, Stuttgart, Germany"},{"name":"University of Split School of Medicine, Split, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David C","family":"Wheeler","sequence":"additional","affiliation":[{"name":"Clinical Effectiveness Group, Centre for Primary Care and Public Health, Queen Mary University of London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Pignot","sequence":"additional","affiliation":[{"name":"Kantar Health GmbH, Real World Research & Value, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgiana","family":"Cornea","sequence":"additional","affiliation":[{"name":"Vifor Pharma Group, Glattbrugg, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Schulmann","sequence":"additional","affiliation":[{"name":"Vifor Pharma Group, Glattbrugg, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars H","family":"Lund","sequence":"additional","affiliation":[{"name":"Department of Medicine, Karolinska Institutet, Stockholm, Sweden"},{"name":"Karolinska University Hospital, Heart and Vascular Theme, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,9,30]]},"reference":[{"key":"2020101306145626500_sfz129-B1","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1159\/000479802","article-title":"Association of serum potassium with all-cause mortality in patients with and without heart failure, chronic kidney disease, and\/or diabetes","volume":"46","author":"Collins","year":"2017","journal-title":"Am J Nephrol"},{"key":"2020101306145626500_sfz129-B2","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s10557-017-6767-5","article-title":"New therapeutic approaches for the treatment of hyperkalemia in patients treated with renin-angiotensin-aldosterone system inhibitors","volume":"32","author":"Tamargo","year":"2018","journal-title":"Cardiovasc Drugs Ther"},{"key":"2020101306145626500_sfz129-B3","first-page":"1","article-title":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of chronic kidney disease","volume":"3","year":"2013","journal-title":"Kidney Int Suppl"},{"key":"2020101306145626500_sfz129-B4"},{"key":"2020101306145626500_sfz129-B5","first-page":"1429","article-title":"The Consensus Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS)","volume":"316","year":"1987","journal-title":"N Engl J Med"},{"key":"2020101306145626500_sfz129-B6","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1001\/archinternmed.2009.132","article-title":"The frequency of hyperkalemia and its significance in chronic kidney disease","volume":"169","author":"Einhorn","year":"2009","journal-title":"Arch Intern Med"},{"key":"2020101306145626500_sfz129-B7","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1016\/j.amjmed.2015.05.040","article-title":"Management of hyperkalemia: an update for the internist","volume":"128","author":"Kovesdy","year":"2015","journal-title":"Am J Med"},{"key":"2020101306145626500_sfz129-B8","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1161\/CIRCULATIONAHA.117.030576","article-title":"Long-term potassium monitoring and dynamics in heart failure and risk of mortality","volume":"137","author":"Nunez","year":"2018","journal-title":"Circulation"},{"key":"2020101306145626500_sfz129-B9","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1093\/eurheartj\/ehq502","article-title":"Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial","volume":"32","author":"Pitt","year":"2011","journal-title":"Eur Heart J"},{"key":"2020101306145626500_sfz129-B10","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1410853","article-title":"Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors","volume":"372","author":"Weir","year":"2015","journal-title":"N Engl J Med"},{"key":"2020101306145626500_sfz129-B11","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(19)32135-X","article-title":"Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial","author":"Agarwal","year":"2019","journal-title":"Lancet"}],"container-title":["Clinical Kidney Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ckj\/article-pdf\/13\/4\/714\/33871550\/sfz129.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ckj\/article-pdf\/13\/4\/714\/33871550\/sfz129.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,13]],"date-time":"2020-10-13T10:21:57Z","timestamp":1602584517000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ckj\/article\/13\/4\/714\/5576156"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,30]]},"references-count":11,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2019,9,30]]},"published-print":{"date-parts":[[2020,8,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ckj\/sfz129","relation":{},"ISSN":["2048-8513"],"issn-type":[{"value":"2048-8513","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,8]]},"published":{"date-parts":[[2019,9,30]]}}}